Giant cell arteritis with visual loss following zoledronic acid infusion.
Zoledronic acid is used in the treatment of osteoporosis. Giant cell artertitis may lead to vision loss. We report a case in which vision loss occurred after zoledronic acid infusion.
Department of Medicine - Rheumatology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Samy
S
Metyas
Makary
M
Ibrahim
John
J
Solyman
Karen C
KC
Yeter
Daniel G
DG
Arkfeld
D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D013700:Giant Cell Arteritis / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects*; D007263:Infusions, Parenteral; D010024:Osteoporosis / Q000188:drug therapy*; D016896:Treatment Outcome; D014786:Vision Disorders / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D014785:Vision, Ocular / Q000187:drug effects*; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D005938:Glucocorticoids; D007093:Imidazoles; D000077211:Zoledronic Acid
clinical aspects; drug treatment; giant cell arteritis; osteoporosis; zoledronic acid